Expression of circulating microRNA-1 and microRNA-133 in pediatric patients with tachycardia

LING SUN1*, SHUO SUN2*, SHAOYING ZENG1, YUFEN LI1, WEI PAN1 and ZHIWEI ZHANG1

Departments of 1Pediatrics and 2Cardiology, Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangzhou, Guangdong 510080, P.R. China

Received October 16, 2013; Accepted May 22, 2014

DOI: 10.3892/mmr.2015.3246

Abstract. Paroxysmal or persistent tachycardia in pediatric patients is a common disease. Certain circulating microRNAs (miRNAs) have been associated with arrhythmia. The present study investigated miRNAs in the plasma of pediatric patients with tachycardia. Forty pediatric subjects were included retrospectively: 24 with recurrent sustained tachycardia [seven cases of ventricular tachycardia (VT) and 17 cases of supraventricular tachycardia (SVT)] and 16 healthy controls. Circulating miR-1 and miR-133 in the plasma were detected by fluorescent quantitative polymerase chain reaction. miR-1 levels were significantly decreased in the arrhythmia group compared with those in the controls (P=0.004) whilst miR-133 expression levels were not significantly different between the two groups (P=0.456). Both miR-1 and miR-133 levels showed significant differences between the SVT and VT groups (P=0.004 and P=0.046, respectively), and a significant decrease in miR-1 levels was observed in the SVT group as compared with the controls (P<0.001). No significant difference was observed in the expression levels of miR-133. By contrast, miR-133 levels were significantly increased in the VT group compared with those in the controls (P=0.024), whereas no statistically significant difference was observed in the expression levels of miR-1. Receiver operating characteristic curves showed that 1/miR-1 was significant for the evaluation of tachycardia. Additionally, miR-1 produced enhanced sensitivity and specificity for the evaluation of VT compared with miR-133, whereas miR-133 was a better marker to assess VT. This study demonstrated that miRNAs may be appropriate markers for pediatric tachycardia; miR-1 levels were decreased in the arrhythmia group compared with those in the healthy controls. Furthermore, patients with SVT had lower miR-1 expression levels while those with VT had higher miR-133 expression levels.

Introduction

Paroxysmal or persistent tachycardia is a common condition in pediatric patients. Pediatric cardiac and non-cardiac diseases, such as anoxia, hydropenia and electrolyte imbalance, can induce arrhythmias (1). Persistent tachycardia can result in serious and potentially fatal pathologies such as heart failure; therefore, timely and effective treatment is of great clinical significance. However, the subjective symptoms of tachycardia, such as a choking sensation in the chest or palpitations, are not as evident in pediatric patients, particularly infants, as those in adult patients (2). This can lead to missed treatment opportunities and can result in severe complications, including arrhythmia, cardiomyopathy and sudden mortality. Thus, finding novel, specific biomarkers of tachycardia has great implications for the early prevention and treatment of this condition in pediatric patients and may reduce the chance of sudden mortality caused by malignant arrhythmias. At present, the treatment of arrhythmias primarily involves drug therapy and radiofrequency catheter ablation. However, this methodology is not preferred for pediatric patients since the organs of the patients are still undergoing development and vascular complications can occur (3,4). Therefore, the use of radiofrequency catheter ablation and drug therapy in the treatment of pediatric arrhythmias is limited. In recent years, clinical studies have begun attempts to control paroxysmal or persistent tachycardia in pediatric patients by gene-targeted therapy, with the aim of improving cardiac function in affected children (5,6).

microRNAs (miRNAs) are a class of single-stranded, endogenous, non-coding RNA molecules containing 20-25 nucleotides. miRNAs are formed by the miRNA-processing enzyme Dicer, from a single-stranded 70-90-base-pair RNA precursor with a hairpin structure. Through incomplete complementary base pairing with the 3'-untranslated region of target mRNA, miRNA can inhibit specific protein translation and expression or induce the degradation of target mRNA (7-9). miRNAs are involved...
in numerous key processes, including early development, cell proliferation, differentiation and apoptosis (10). To date, tissue-specific miRNAs identified in the heart have included miR-1, miR-133a/b and miR-208 (11,12). Additionally, the specific expression of circulating miRNAs has been found in various types of cancer and cardiac diseases (13). However, this study, to the best of our knowledge, is the first to report the levels of miRNAs in the plasma of pediatric patients with recurrent sustained tachycardia symptoms. Finding specific markers of tachycardia is particularly important for the early diagnosis and treatment of this disease in children.

Materials and methods

Blood specimen collection. This study was approved by the Ethics Committee of the Institute of Cardiovascular Diseases, Guangdong General Hospital (Guangzhou, China). The families of all pediatric patients that were included in this study signed an informed consent form. Blood specimens were collected from 40 pediatric patients between October 2012 and April 2013. The patients included 16 normal, healthy children with normal electrocardiograms (ECGs) and no history of cardiovascular disease (control group) and 24 children with recurrent sustained tachycardia who were not receiving radiofrequency ablation or antiarrhythmic drug therapy (experimental group). An ECG of the pediatric patients taken at the onset of tachycardia was used as the diagnostic criterion. Blood specimens were centrifuged within 2 h of collection (1,358 x g, 10 min, 4˚C). The separated plasma and blood cells were dispensed into Eppendorf tubes and stored at -80˚C prior to use.

Primer design and synthesis. miR-1, miR-133 and U6 gene sequences were retrieved from the miRBase database (http://www.mirbase.org/) and used as a reference for designing the polymerase chain reaction (PCR) primers. The designed primers were synthesized by Shanghai Invitrogen Biotechnology Co., Ltd (Shanghai, China). The primer sequences were as follows: miR-1 forward primer, 5'-ACACTCCAGCTGGGATAGTGAAGAAGT-3' and reverse primer, 5'-TCAACTGGTGTCAGCTGCATCCAGATGTCGGAATCTTGGACAGCTGTT-3'; miR-133 forward primer, 5'-ACACTCCAGCTGGGATAGTGAAGAAGT-3' and reverse primer, 5'-CTCAAAGTTGTTCTCCATCACTACAGG-3'; miR-133 reverse primer, 5'-CTCAACTGGTGTCAGCTGCATCCAGATGTCGGAATCTTGGACAGCTGTT-3'; reverse universal primer UR1, 5'-TGGTGTTCTCGAGGAGTCCG-3'; internal reference U6 forward primer, 5'-TGCTCGTCGTCAGGTCCACAGCAACCG-3' and U6 reverse primer, 5'-AACGGTTCAGGAGTCTGCAGGCAGG-3'. The downstream primers of miR-1, miR-133 and U6 were mixed in equal volumes to obtain a concentration of 10 µM for each primer.

Reverse transcription (RT) and fluorescent quantitative PCR (qPCR). Total RNA was extracted from the plasma using TRIzol® LS reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The total RNA was subjected to reverse transcription (RT) by PCR immediately subsequent to extraction. The 20-µl RT-PCR reaction system (ReverTra Ace-α-Reverse Transcription kit; Toboyo Co., Ltd., Osaka, Japan) contained 2 µl 10X buffer, 1 µl 2.5 mM deoxynucleotide triphosphate, 3 µl mixed downstream primer, 0.5 µl reverse transcriptase Moloney murine leukemia virus and 13.5 µl RNA template. The RT-PCR program comprised 25˚C for 15 min followed by 50˚C for 50 min. A total of 2 µl RT product (cDNA) was utilized for qPCR. The 20-µl reaction systems for the qPCR detection of miR-1, miR-133 and U6 contained 10 µl SYBR Premix Taq II (2X; Takara Bio, Inc., Shiga, Japan), 0.2 µl 30 pmol/µl upstream primer, 0.2 µl 30 pmol/µl downstream primer, 7.6 µl dH2O and 2 µl cDNA. The fluorescent qPCR program comprised 95˚C for 5 min, followed by 40 cycles of 94-80˚C (94˚C for 10 sec, 55˚C for 20 sec, 72˚C for 10 sec and 80˚C for 35 sec) using an ABI 7500 fluorescent quantitative PCR machine in plate read mode (Applied Biosystems Life Technologies, Foster City, CA, USA), which identifies genotypes, detects gene locus mutations and analyzes single nucleotide polymorphisms. The program ended with the preparation of a melting curve at 60-95˚C.

Statistical analysis. The standard curves of miR-1 and miR-133 were used to calculate the absolute quantities of miR-1 and miR-133. The levels of circulating miR-1 and miR-133 in the plasma are expressed as the mean ± standard deviation. Measurement data were analyzed by the independent two-sample t-test with P<0.05 considered statistically significant. The sensitivity of miR-1 and miR-133 to arrhythmia was tested with receiver operating characteristic (ROC) curves. All data were processed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA) statistical software.

Results

Baseline data. This study included 40 pediatric patients: 24 with arrhythmia and 16 healthy controls (24 males and 16 females) with average ages of 6.6±3.9 and 9.8±1.8 years in the arrhythmia and control groups, respectively. In the arrhythmia group, there were seven cases of ventricular tachycardia and 17 cases of supraventricular tachycardia (SVT). Baseline data of the pediatric patients are shown in Table I.

Circulating miRNA levels in the plasma of pediatric patients. The standard curves prepared by double dilution of miR-1 and miR-133 standards (y, cycle threshold value; x, Log initial copies; CO) are shown in Fig. 1. The amplification and melting curves for the qPCR are shown in Figs. 2 and 3.

Table I. Baseline data of the pediatric patients.

|                  | Arrhythmic | Non-arrhythmic |
|------------------|------------|---------------|
| Number           | 24         | 16            |
| Gender (n male/n female) | 15/9       | 9/7           |
| Age (years)      | 6.6±3.9    | 9.8±1.8       |

The miR-1 levels in the plasma of pediatric patients showed a significant difference between the arrhythmia and non-arrhythmia groups (3.09x10^4±2.11x10^4 vs. 5.16x10^6±1.99x10^6 copies/ml, P=0.004), whereas no
Table II. miR-1 and miR-133 levels in the plasma of pediatric patients.

| miR type | Arrhythmic (copies/ml) | Non-arrhythmic (copies/ml) | P-value |
|----------|------------------------|---------------------------|---------|
| miR-1    | 3.09x10^6±2.11x10^6    | 5.16x10^6±1.99x10^6       | 0.004*  |
| miR-133  | 1.34x10^6±4.74x10^5    | 1.43x10^6±2.03x10^5       | 0.456   |

*Indicates statistical significance. miR, microRNA.

Figure 1. Standard curves for (A) miR-1 and (B) miR-133. miR-1, y=-3.186442+40.348274x (R^2=0.988156); miR-133, y=-3.289124+37.668317x (R^2=0.995739). miR, microRNA; Ct, cycle threshold; CO, initial copies.

Figure 2. microRNA-1 (A) amplification and (B) melting curves from SYBR quantitative polymerase chain reaction detection.

Figure 3. microRNA-133 (A) amplification and (B) melting curves from SYBR quantitative polymerase chain reaction detection.

Statistically significant differences were observed in the miR-133 levels between the two groups (1.34x10^6±4.74x10^5 vs. 1.43x10^6±2.03x10^5 copies/ml, P=0.456) (Table II). The above results indicate that miR-1 levels were decreased in the plasma.
of the patients with arrhythmia whereas miR-133 levels exhibited no significant variation (Fig. 4).

**miRNA levels in the plasma of pediatric patients of different genders.** The levels of miR-1 and miR-133 in the plasma of pediatric patients with arrhythmia showed no statistically significant differences between the males and females (miR-1, $3.86 \times 10^6 \pm 2.41 \times 10^6$ vs. $4.01 \times 10^6 \pm 2.15 \times 10^6$ copies/ml, $P=0.842$; miR-133, $1.33 \times 10^6 \pm 3.47 \times 10^5$ vs. $1.45 \times 10^6 \pm 4.44 \times 10^5$ copies/ml, $P=0.351$) (Table III). The frequency distribution of miR-1 and miR-133 in the plasma of male and female pediatric patients with arrhythmia and controls is shown in Fig. 5.

**Sensitivity and specificity of 1/miRNA for the evaluation of arrhythmia (ROC curve).** ROC curves were prepared with 1/miR-1 and 1/miR-133. Arrhythmia was defined as the positive event (Fig. 6). The results showed that the diagnosis of tachycardia with 1/miR-1 had statistical significance ($P=0.004$; area under the ROC curve, 0.773; 95% confidence interval of the area, 0.630-0.917), whereas the diagnosis of tachycardia

### Table III. miR-1 and miR-133 levels in the plasma of male and female pediatric patients.

| miR type | Male (copies/ml)       | Female (copies/ml)      | P-value |
|----------|------------------------|-------------------------|---------|
| miR-1    | $3.86 \times 10^6 \pm 2.41 \times 10^6$ | $4.01 \times 10^6 \pm 2.15 \times 10^6$ | 0.842   |
| miR-133  | $1.33 \times 10^6 \pm 3.47 \times 10^5$ | $1.45 \times 10^6 \pm 4.44 \times 10^5$ | 0.351   |

N=40 patients; male, n=24; female, n=16. miR, microRNA.
with 1/miR-133 had no statistical significance (P=0.73) (Table IV).

**Subgroup analysis of miRNA levels in the plasma of patients with arrhythmia.** Subgroup analysis was performed on the pediatric patients with arrhythmia for the comparison of plasma miR-1 and miR-133 levels between the SVT and VT groups (Table V). Statistically significant differences were observed in the miR-1 and miR-133 levels in the plasma between the SVT and VT groups (miR-1, 2.41x10^6±1.62x10^4 vs. 4.76x10^6±2.36x10^6 copies/ml, P=0.004; miR-133, 1.22x10^6±5.08x10^5 vs. 1.64x10^6±1.69x10^5 copies/ml, P=0.046). In addition, statistically significant differences in plasma miR-1 levels were observed between the patients with SVT and the control group (2.41x10^6±1.62x10^6 vs. 5.16x10^5±1.99x10^5 copies/ml, P<0.001) (Table VI), whereas the plasma miR-133 levels showed no significant difference between these two groups. The expression levels of miR-133 in the plasma were, however, significantly different between the VT and normal control groups (1.64x10^6±1.69x10^5 vs. 1.43x10^6±2.03x10^5 copies/ml, P=0.024) (Table VII), whereas no significant difference was observed in the plasma miR-1 levels between these two groups. Together, these results indicate that circulating miR-1 levels in the plasma of pediatric patients with SVT were downregulated, whereas miR-133 levels in the plasma of pediatric patients with VT were upregulated.

**Sensitivity of ROC curves for the evaluation of SVT and VT.** According to the ROC curves, miR-1 had enhanced sensitivity and specificity for the evaluation of SVT (P<0.001; area under the ROC curve, 0.826; 95% confidence interval of the area, 0.699-0.953) (Fig. 7A), whereas miR-133 had better sensitivity and specificity for the evaluation of VT (P=0.01; area under
miRNAs regulate cell proliferation and differentiation by mRNA-specific base pairing and their expression exhibits cell or tissue specificity (14‑16). Studies have demonstrated that numerous miRNAs are involved in the reconstruction of ion channels by regulating gene expression in cardiomyocytes during the process of arrhythmia (17‑19). At present, studies on the association between miRNA and arrhythmia are primarily focusing on pathological and physiological processes such as myocardial ischemia and cardiac hypertrophy (20‑23). The interactions of miRNAs with ion channel-encoding genes and calmodulin regulate cardiac contractility, rhythm and excitement, thereby inducing arrhythmia (24,25). However, less research has been undertaken into arrhythmia in pediatric patients without organ disease, and, to the best of our knowledge, no reports are available on the specific expression of circulating miRNA in pediatric patients with persistent tachycardia.

In the present study, miR-1 and miR-133 levels in the plasma of pediatric patients with tachycardia and healthy controls were quantitatively detected by a qPCR. The results showed that circulating miR-1 levels in the plasma were lower in the patients with arrhythmia than those in the healthy controls, whilst no significant differences were observed in the miR-133 expression levels. Of note, the results of the subgroup analysis revealed that there were significant differences in circulating miR-1 levels in the plasma of pediatric patients between the SVT and VT groups. Additionally, circulating plasma miR-1 levels were decreased in patients with SVT, whereas plasma miR-133 levels were unchanged.
levels were significantly increased in patients with VT, as compared with those in the normal controls. Together, these results demonstrate that different circulating miRNAs in the plasma of pediatric patients with SVT and VT may cause the reconstruction of various ion channels, thereby inducing arrhythmias of different types.

Myocardial ischemia-induced arrhythmia is a major cardiovascular pathology associated with miR-1 and miR-133. It has been reported that miR-1 expression is significantly increased in patients with myocardial ischemia and infarction and is causative of arrhythmias. A possible mechanism for this is that the ischemia-related abnormally high expression of miR-1 leads to a reduction in gap junction α-1 protein/Connexin43 expression and a delay in cardiac conduction, as well as to a reduction in potassium inwardly-rectifying channel, subfamily J, member 2 expression, a decline in inward rectifier current density and resting potential rise, ultimately leading to the occurrence of ischemic arrhythmia (26-29). Zhang et al (30) found in an animal model of myocardial ischemia that miR-1 overexpression in the ventricular heart muscle caused atrioventricular block; the underlying mechanism was associated with a reduction in Connexin43 expression and a decline in L-type Ca

The identification of specific miRNAs has provided a novel perspective for studying the pathogenesis of arrhythmia. Accordingly, new ideas have been considered for the future development of novel, secure and effective drugs for treating arrhythmia. The expression of specific circulating miRNA in plasma has great medical significance for early arrhythmia prevention. In the near future, gene-targeted therapy and the prevention of arrhythmia in pediatric patients are likely to have great benefit.

References

1. Balaguer Gargallo M, Jordán García I, Caritg Bosch J, et al.: Supraventricular tachycardia in infants and children. An Pediatr (Barc) 67: 133-138, 2007 (In Spanish).
2. Calabrò MP1, Cerrito M, Luzzo F, et al.: Supraventricular tachycardia in infants: epidemiology and clinical management. Curr Pharm Des 14: 723-728, 2008.
3. Weindling SN, Saul JP and Walsh EP: Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and infants. Am Heart J 131: 66-72, 1996.
4. Kugler JD, Danford DA, Deal BJ, et al.: Radiofrequency catheter ablation for tachyarrhythmias in children and adolescents. N Engl J Med 330: 1481-1487, 1994.
5. Schwartz P, Crotti L and Insolia R: Arrhythmogenic disorders of genetic origin: long QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol 5: 868-873, 2012.
6. Shimizu W and Horie M: Phenotypical manifestations of mutations in genes encoding subunits of cardiac potassium channels. Circ Res 109: 97-109, 2011.
7. Meister G and Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343-349, 2004.
8. Alvarez-Garcia I and Miska EA: MicroRNA functions in animal development and human disease. Development 132: 4653-4662, 2005.
9. Miranda KC, Huynh T, Tay Y, et al.: A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126: 1203-1217, 2006.
10. Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33: 1290-1297, 2005.
11. da Costa Martins PA, Leptidis S, Salic K and De Windt LJ: MicroRNA regulation in cardiovascular disease. Curr Drug Targets 11: 900-906, 2010.
12. Ikeda S and Pu WF: Expression and function of microRNAs in heart disease. Curr Drug Targets 11: 913-925, 2010.
13. Jazbutyte V and Thum T: MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets 11: 926-935, 2010.
14. Lagos-Quintana M, Rauhut R, Yalcin A, et al: Identification of tissue-specific microRNAs from mouse. Curr Biol 12: 735-739, 2002.
15. Marsit CJ, Eddy K, Kelsey KT: MicroRNA responses to cellular stress. Cancer Res 66: 10843-10848, 2006.
16. Etheridge A, Lee I, Hood L, et al: Extracellular microRNA: a new source of biomarkers. Mutat Res 717: 85-90, 2011.
17. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J and Olson EN: Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316: 575-579, 2007.
18. van Rooij E, Quiat D, Johnson BA, et al: A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 17: 662-673, 2009.
19. Luo X, Zhang H, Xiao J and Wang Z: Regulation of human cardiac ion channel genes by microRNAs: theoretical perspective and pathophysiological implications. Cell Physiol Biochem 25: 571-586, 2010.
20. Ye Y, Hu Z, Lin Y, et al: Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 87: 535-544, 2010.
21. Qin Y, Yu Y, Dong H, et al: MicroRNA 21 inhibits left ventricular remodeling in the early phase of rat model with ischemia-reperfusion injury by suppressing cell apoptosis. Int J Med Sci 9:4 13-423, 2012.
22. Zhang X, Wang X, Zhu H, et al: Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J Mol Cell Cardiol 49: 841-850, 2010.
23. Ganesan J, Ramanujam D, Sassi Y, et al: MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127: 2097-2106, 2013.
24. Luo X, Zhang H, Xiao J, et al: Regulation of human cardiac ion channel genes by microRNAs: theoretical perspective and pathophysiological implications. Cell Physiol Biochem 25: 571-586, 2010.
25. Terentyev D, Belevych AE, Terentyeva R, et al: miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B50alpha and causing CaMKII dependent hyperphosphorylation of RyR2. Circ Res 104: 514-521, 2009.
26. Ai J, Zhang R, Li Y, et al: Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 391: 73-77, 2010.
27. Wang GK, Zhu JQ, Zhang JT, et al: Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31: 659-666, 2010.
28. D’Alessandra Y, Pompilio G and Capogrossi MC; MicroRNAs and myocardial infarction. Curr Opin Cardiol 27: 228-235, 2012.
29. Iekushi K, Seeger F, Assmus B, Zeiher AM and Dimmeler S: Regulation of cardiac microRNAs by bone marrow mononuclear cell therapy in myocardial infarction. Circulation 125: 1765-1773, S1-S7, 2012.
30. Zhang Y, Sun L, Zhang Y, et al: Overexpression of microRNA-1-ncues atrioventricular block in rodents. Int J Biol Sci 9: 455-462, 2013.
31. Boyett MR, Inada S, Yoo S, et al: Connexins in the sinoatrial and atrioventricular nodes. Adv Cardiol 42: 175-197, 2006.
32. Luo X, Lin H, Pan Z, et al: Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem 283: 20045-20052, 2008.
33. Xiao J, Yang B, Lin H, Lu Y, Luo X and Wang Z: Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 212: 285-292, 2007.
34. Li Y, Yang CM, Xi Y, et al: MicroRNA-1/133 targeted dysfunction of potassium channels KCNE1 and KCNQ1 in human cardiac progenitor cells with simulated hyperglycemia. Int J Cardiol 167: 1076-1078, 2013.
35. Matkovich SJ, Wang W, Tu Y, et al: MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 106: 166-175, 2010.
36. Xiao J, Luo X, Lin H, et al: MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 282: 12363-12367, 2007.
37. Stauffer BL, Sobus RD and Sucharov CC: Sex differences in cardiomyocyte connexin 43 expression. J Cardiovasc Pharmacol 58: 32-39, 2011.